Cencora Inc.

Cencora Inc.

COR

Get informed when a big investor buys or sells

+ Follow
Market Cap$52.89B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Cencora Inc.Cencora Inc.20.70.86%75%0.23.7

Earnings Call Q2 2026

May 6, 2026 - AI Summary

Strong quarter + EPS outperformance; raised full-year EPS guidance - Adjusted diluted EPS: $4.75 in Q2, +7.5% YoY. - Full-year fiscal 2026 adjusted diluted EPS guidance raised to $17.65–$17.90 (from $17.45–$17.75). - Consolidated revenue $78.4B (+4% YoY); operating income +$6% YoY to $1.3B. - Cash/FCF: ended March with $2.2B cash and generated $1.1B adjusted free cash flow in the March quarter; full-year adjusted free cash flow guidance remains ~$3B (unchanged).
Guidance update: revenue slightly down, operating income growth up - Revenue growth guidance reduced to 4%–6% (from 7%–9%), mainly due to: - Faster-than-expected brand conversions at a large mail-order pharmacy customer (noted as contributing to lower revenue growth; also discussed as lower-margin impact). - Slower GLP-1 growth vs prior expectations. - Continued manufacturer WACC/IRA-related price reductions (explicitly referenced: $2B IRA/WACC headwind in Q2). - Operating income growth guidance increased to 12%–14% (from 11.5%–13.5%)—helped by “Other” strength and accounting impacts: - MWI Animal Health classified as “asset held for sale” → depreciation suspended, boosting operating income growth. - Segment outlook: U.S. revenue 4%–6%; International revenue 8%–10% (as-reported) / 6%–8% constant currency. International operating income outlook unchanged (5%–8%).
Near-term catalysts for acceleration (but with transitory noise) - Q2 results were impacted by several transitory items (management repeatedly emphasized they are not changing long-term operating profit confidence): - Lost oncology customer (from acquisition): headwind still not fully lapped; management said if excluding oncology loss and OneOncology acquisition impact, U.S. operating income growth would have been ~7%. - Weather-related appointment disruptions: estimated ~$10M headwind to U.S. operating income; rebound seen in March and improving trends into April. - COVID vaccine timing: ~$10M operating income headwind (vs +$15M contribution in same quarter last year). - Second-half confidence drivers: lapping oncology customer loss, OneOncology accretion ramp, easier U.S. expense comps in Q4, and continued rebound in global specialty logistics internationally.

Exclusive for Stockcircle Pro members

Sign upSign Up
$362.50

Target Price by Analysts

29% upsideCencora Target Price DetailsTarget Price
$711.48

Current Fair Value

153.1% upside

Undervalued by 153.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$52.89 Billion
Enterprise Value$63.39 Billion
Dividend Yield$2.35 (0.86%)
Earnings per Share$8.02
Beta0.59
Outstanding Shares194,545,000

Return

Return on Equity75.01%ROE
Return on Assets3.12%
Return on Invested Capital10.10%

Valuation & Multiples

P/E Ratio20.72P/E Ratio
PEG16.11PEG
Price to Sales0.17Price to Sales
Price to Book Ratio15.62Price to Book Ratio
Enterprise Value to Revenue0.19
Enterprise Value to EBIT24.59
Enterprise Value to Net Income24
Total Debt to Enterprise0.2
Debt to Equity3.75Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 6, 2026
EPS Estimate
$4.82
Average shareholder expectation
Revenue Estimate
$81.09 B
Average shareholder expectation

Next Earnings Call

Expected Date
August 5, 2026
EPS Estimate
$4.35
Average shareholder expectation
Revenue Estimate
$84.36 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.5316▼ 17.36%
Total Calls807,928▼ 56.40%
Total Puts429,475▼ 67.13%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %94.21%▲ 0.03%
Total Invested$57.34B▼ 7.05%
Investors Holding1,471▼ 44.00%

ESG Score

No data

About CoreSite Realty Corporation

CEO: Paul Szurek

Relevant Senate Committees

Joint Committee on Taxation

This non-partisan committee provides official 'revenue estimates' for all tax bills and influences corporate tax structures and capital investment credits. Its technical expertise directly impacts the tax burden on financial markets and industries, making it highly relevant for 'Other Financial Vehicles' and their investment strategies.

Finance

This powerful committee controls taxation, trade, and entitlement spending. It directly drives corporate valuations through tax policy and impacts capital markets, making it highly relevant for 'Finance and Insurance' companies and the performance of 'Other Financial Vehicles'.

Agriculture, Nutrition, and Forestry

This committee oversees the CFTC and regulates the massive derivatives/futures market. Crucially, it is a key player in defining cryptocurrencies as digital commodities. This is directly impactful for 'Other Financial Vehicles' involved in derivatives, commodities, or cryptocurrency markets.

Banking, Housing, and Urban Affairs

This committee is the primary regulator for the entire financial system, including the Fed, SEC, and HUD. It drives bank capital requirements, cryptocurrency regulation, and real estate markets. Any entity in 'Finance and Insurance' and 'Other Financial Vehicles' is directly subject to its oversight and policy decisions.

Foreign Relations

This committee guides U.S. foreign policy and issues sanctions legislation which heavily impacts global markets, energy prices, and international banking access. Financial vehicles often have international exposure or are affected by geopolitical risks, making information from this committee highly relevant.